Aspirin、clopidogrel、placebo or SHR2285 + Aspirin、clopidogrel、placebo or SHR2285 + Aspirin、ticagrelor、placebo or SHR2285
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Thrombosis
Conditions
Thrombosis
Trial Timeline
Jul 13, 2021 → Jun 15, 2022
NCT ID
NCT04945616About Aspirin、clopidogrel、placebo or SHR2285 + Aspirin、clopidogrel、placebo or SHR2285 + Aspirin、ticagrelor、placebo or SHR2285
Aspirin、clopidogrel、placebo or SHR2285 + Aspirin、clopidogrel、placebo or SHR2285 + Aspirin、ticagrelor、placebo or SHR2285 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04945616. Target conditions include Thrombosis.
What happened to similar drugs?
8 of 20 similar drugs in Thrombosis were approved
Approved (8) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04945616 | Phase 1 | Completed |
Competing Products
20 competing products in Thrombosis